juli for Biopharma

Engage chronic condition patients with a clinically-validated app & platform

Proven efficacy across conditions in 2 clinical trials

Over 500 patients with depression or asthma utilized juli for 8 weeks in two separate randomized controlled trials (RCTs) conducted by University College of London, getting either the full app or a very limited control version.

Both studies reached their primary endpoint of statistically significantly better improvements on PHQ-8 and ACT scores compared to an active control.

In the depression RCT the usage of juli additionally led to 51% of the users achieving remission. 

In the asthma RCT, juli users were twice as likely to achieve score reductions of 3 points or more on ACT.

Both studies submitted for peer-reviewed publication. Preprints can be downloaded here: 

Loved by users: Outstanding retention and engagement

It remains a challenge to keep patients actively using digital  apps for any length of time. A recent large-scale Stanford-led study on cardiovascular health showed that on average usage for apps is only 4.1 days. 

Our use of evidence-based techniques, extensive research and user testing has optimized juli’s retention and engagement rates. On average, juli members use the app over 2 times a week. 

juli retention is  7x
health industry average

juli tracks and reminds users
to support medication adherence

Users are prompted to add  their medication (name, dosing and frequency) and asked to set customizable reminders that fit their schedule.

Beyond adherence, juli helps users see the benefit of medication use by correlating it to outcomes improvements. 

A combination of evidence-based approaches

  • Easy data collection with largely passively-sensed data, combined with self-reported plus hyperlocal environmental data

  • Dashboard with assessments and pattern recognition

  • AI-derived recommendations for individual behavioral changes in gamified environment

  • Supports medication adherence

Caring for many conditions and their comorbidities

28,000+ users downloaded juli for one of the following conditions:

Anxiety Disorder, Asthma, Bipolar Disorder, Chronic Pain, COPD, Depression, Hypertension, Migraine, Musculoskeletal Pain, Nerve Pain, Non-Migraine Headache, Pain of Unknown Origin, Visceral Pain

Many more are in development. juli also covers comorbidities between these conditions.

Built for customization and white-labeling

Flexible platform allows us to add new conditions within weeks using clinically validated scales and interactions.

Co-branding and white-labeling allows tailoring to our customers’ unique markets and patient segments.